Cancer Immunotherapy Market by Technology (Monoclonal Antibodies, Cytokines & Immunomodulators, and Others), by Application (Lung Cancer, Breast Cancer, Colorectal Cancer, Melanoma, Prostate Cancer, Head & Neck Cancer, and Others) by End User (Hospitals, Cancer Research Centers, and Clinics) - Global Opportunity Analysis and Industry Forecast, 2014-2022

May 2017 | 150 pages | ID: C95BAC0ABE8EN
Allied Market Research

Abstracts

The global cancer immunotherapy market is accounted for $45,471 million in 2015, and is estimated to reach $117,114 million by 2022, growing at a CAGR of 14.5% during the analysis period of 2016-2022. Cancer Immunotherapy is a method of cancer treatment that boosts the immune system in fighting cancer. This therapy is more advantageous than the traditional approach as it delivers long-term protection against cancer, has minimal side effects, and avails treatment to more cancer types. Immunotherapy works by guiding system toward cancer-specific targets, followed by activation of immune system to mobilize the target, and produces response that can eradicate cancer targeted cells. There are many factors, such as increase in incidence of cancer, rise in healthcare expenditure, increased access to medical insurance, and technological advancements in cancer treatment therapies that fuel the growth of the global cancer immunotherapy market. However, the factors such as lack of awareness about cancer immunotherapy are anticipated to inhibit the growth of the market. Also, the high product developmental cost is expected to impede the growth of the market.

The market is segmented based on technology, application, end-users, and geography. By technology, this market is categorized into monoclonal antibodies, cytokines & immunomodulators, and other technologies. By application, it is classified into lung cancer, breast cancer, colorectal cancer, melanoma, prostate cancer, head & neck cancer, and other applications. By end-users, it is divided into hospitals, cancer research centers, and clinics. Geographically, it is studied across North America, Europe, Asia Pacific, and LAMEA.

KEY MARKET BENEFITS:

• Comprehensive analysis of factors that drive and restrict the growth of the global cancer immunotherapy market is provided.
• The projections in the market are made by studying the current market trends and future market potential for the period (2014-2022) in terms of value.
• Extensive analysis by technology and application helps understand the various trends and prevailing opportunities in the respective market
• Key market players within the global cancer immunotherapy market are profiled in the market and their strategies are analyzed thoroughly, which helps understand the competitive outlook of the global cancer immunotherapy market.
• Comprehensive analysis of all regions are provided that determines the prevailing opportunities in these geographies.

KEY MARKET SEGMENT:
By Technology

• Monoclonal Antibodies
• Cytokines & Immunomodulators
• Others (Immune Checkpoint Inhibitors, Cell Therapy, and Oncolytic Virus Immunotherapy)

By Application

• Lung Cancer
• Breast Cancer
• Colorectal Cancer
• Melanoma
• Prostate Cancer
• Head & Neck Cancer
• Others (Renal Cell Carcinoma, Cervical, Gastric, and Lymphoma)

By End-Users

• Hospitals
• Cancer Research Centres
• Clinics

By Geography

• North America
• U.S.
• Canada
• Mexico
• Europe
• Germany
• U.K.
• France
• Spain
• Italy
• Others
• Asia Pacific
• Japan
• China
• India
• Others
• LAMEA
• Latin America
• Middle East
• Africa

List of players profiled in the report

• F. Hoffmann-La Roche AG.
• Advaxis Inc.
• Merck & Co., Inc.
• Eli Lilly and Company
• Bristol-Myers Squibb Company
• Pfizer Inc.
• Novartis AG
• Bayer AG
• Immunomedics Inc.
• Astrazeneca plc.

List of other players (These companies are not profiled in the report and same can be done on demand)

• Seattle Genetics
• Peregrine Pharmaceuticals
• Viralytics Ltd.
• Takeda Pharmaceutical Company Ltd.
• Amgen Inc.

Contents

CHAPTER 1 INTRODUCTION

1.1. REPORT DESCRIPTION
1.2. KEY BENEFITS
1.3. KEY MARKET SEGMENT
1.4. RESEARCH METHODOLOGY
  1.4.1. Secondary research
  1.4.2. Primary research
1.5. ANALYST TOOLS AND MODELS

CHAPTER 2 EXECUTIVE SUMMARY

2.1. KEY FINDINGS OF THE STUDY
2.2. CXO PERSPECTIVE

CHAPTER 3 MARKET OVERVIEW

3.1. MARKET DEFINITION AND SCOPE
3.2. KEY FINDINGS
  3.2.1. Top investment pockets
  3.2.2. Top winning strategies
3.3. PORTERS FIVE FORCES ANALYSIS
  3.3.1. Bargaining power of buyers
  3.3.2. Bargaining power of suppliers
  3.3.3. Threat of substitutes
  3.3.4. Threat of new entrants
  3.3.5. Competitive rivalry
3.4. MARKET SHARE ANALYSIS OF CANCER IMMUNOTHERAPY MARKET, 2015
3.5. MARKET DYNAMICS
  3.5.1. Drivers
  3.5.2. Restraints
  3.5.3. Opportunities

CHAPTER 4 CANCER IMMUNOTHERAPY MARKET, BY TECHNOLOGY

4.1. OVERVIEW
  4.1.1. Market Size and Forecast
4.2. MONOCLONAL ANTIBODIES
  4.2.1. Key Market Trends
  4.2.2. Key Growth Factors and Opportunities
  4.2.3. Market Size and Forecast
4.4. CYTOKINES & IMMUNOMODULATORS
  4.4.1. Key Market Trends
  4.4.2. Key Growth Factors And Opportunities
  4.4.3. Market Size And Forecast
4.5. OTHER TECHNOLOGY
  4.5.1. Key Market Trends
  4.5.2. Key Growth Factors And Opportunities
  4.5.3. Market Size And Forecast

CHAPTER 5 CANCER IMMUNOTHERAPY MARKET, BY APPLICATION

5.1. OVERVIEW
  5.1.1. Market size and forecast
5.2. LUNG CANCER
  5.2.1. Market size and forecast
5.3. BREAST CANCER
  5.3.1. Market size and forecast
5.4. COLORECTAL CANCER
  5.4.1. Market size and forecast
5.5. MELANOMA
  5.5.1. Market size and forecast
5.6. PROSTATE CANCER
  5.6.1. Market size and forecast
5.7. HEAD & NECK CANCER
  5.7.1. Market size and forecast
5.8. OTHER CANCER
  5.8.1. Market size and forecast

CHAPTER 6 CANCER IMMUNOTHERAPY MARKET, BY END USER

6.1. OVERVIEW
  6.1.1. Market size and forecast
6.2. HOSPITAL
  6.2.1. Market size and forecast
6.3. CANCER RESEARCH CENTERS
  6.3.1. Market size and forecast
6.4. CLINICS
  6.4.1. Market size and forecast

CHAPTER 7 MULTIPLEX ASSAYS MARKET, BY GEOGRAPHY

7.1. OVERVIEW
  7.1.1. Market size and forecast
7.2. NORTH AMERICA
  7.2.1. Key market trends
  7.2.2. Key growth factors and opportunities
  7.2.3. Market size and forecast
  7.2.4. U.S. market size and forecast
  7.2.5. Canada market size and forecast
  7.2.6. Mexico market size and forecast
7.3. EUROPE
  7.3.1. Key market trends
  7.3.2. Key growth factors and opportunities
  7.3.3. Market size and forecast
  7.3.4. Germany market size and forecast
  7.3.5. France market size and forecast
  7.3.6. UK market size and forecast
  7.3.7. Italy market size and forecast
  7.3.8. Spain market size and forecast
  7.3.9. Rest of Europe market size and forecast
7.4. ASIA-PACIFIC
  7.4.1. Key market trends
  7.4.2. Key growth factors and opportunities.
  7.4.3. Market size and forecast
  7.4.4. Japan market size and forecast
  7.4.5. China market size and forecast
  7.4.6. India market size and forecast
  7.4.7. Rest of Asia-Pacific market size and forecast
7.5. LAMEA
  7.5.1. Key market trends
  7.5.2. Key growth factors and opportunities
  7.5.3. Market size and forecast
  7.5.4. Latin America market size and forecast
  7.5.5. Middle East market size and forecast
  7.5.6. Africa market size and forecast

CHAPTER 8 COMPANY PROFILES

8.1. AMGEN INC.
  8.1.1. Company overview
  8.1.2. Company snapshot
  8.1.3. Operating business segments
  8.1.4. Product portfolio
  8.1.5. Business performance
  8.1.6. Key strategic moves and developments
8.2. ADVAXIS INC.
  8.2.1. Company overview
  8.2.2. Company snapshot
  8.2.3. Operating business segments
  8.2.4. Product portfolio
  8.2.5. Business performance
  8.2.6. Key strategic moves and developments
8.3. MERCK & CO., INC.
  8.3.1. Company overview
  8.3.2. Company snapshot
  8.3.3. Operating business segments
  8.3.4. Product portfolio
  8.3.5. Business performance
  8.3.6. Key strategic moves and developments
8.4. ELI LILLY AND COMPANY
  8.4.1. Company overview
  8.4.2. Company snapshot
  8.4.3. Operating business segments
  8.4.4. Product portfolio
  8.4.5. Business performance
  8.4.6. Key strategic moves and developments
8.5. BRISTOL-MYERS SQUIBB COMPANY
  8.5.1. Company overview
  8.5.2. Company snapshot
  8.5.3. Operating business segments
  8.5.4. Product portfolio
  8.5.5. Business performance
  8.5.6. Key strategic moves and developments
8.6. PFIZER INC.
  8.6.1. Company overview
  8.6.2. Company snapshot
  8.6.3. Operating business segments
  8.6.4. Product portfolio
  8.6.5. Business performance
  8.6.6. Key strategic moves and developments
8.7. NOVARTIS AG
  8.7.1. Company overview
  8.7.2. Company snapshot
  8.7.3. Operating business segments
  8.7.4. Product portfolio
  8.7.5. Business performance
  8.7.6. Key strategic moves and developments
8.8. BAYER AG
  8.8.1. Company overview
  8.8.2. Company snapshot
  8.8.3. Operating business segments
  8.8.4. Product portfolio
  8.8.5. Business performance
  8.8.6. Key strategic moves and developments
8.9. IMMUNOMEDICS INC.
  8.9.1. Company overview
  8.9.2. Company snapshot
  8.9.3. Operating business segments
  8.9.4. Product portfolio
  8.9.5. Business performance
  8.9.6. Key strategic moves and developments
8.10. ASTRAZENECA PLC.
  8.10.1. Company overview
  8.10.2. Company snapshot
  8.10.3. Operating business segments
  8.10.4. Product portfolio
  8.10.5. Business performance
  8.10.6. Key strategic moves and developments

List Of Tables

LIST OF TABLES

TABLE 1. GLOBAL CANCER IMMUNOTHERAPY MARKET, BY TECHNOLOGY, 2014-2022, ($MILLION)
TABLE 2. GLOBAL CANCER MONOCLONAL ANTIBODIES MARKET, FOR, BY REGION, 2014-2022, ($MILLION)
TABLE 3. GLOBAL CANCER CYTOKINES & IMMUNOMODULATORS MARKET, BY REGION, 2014-2022, ($MILLION)
TABLE 4. GLOBAL OTHER CANCER IMMUNOTHERAPY MARKET, BY REGION, 2014-2022, ($MILLION)
TABLE 5. GLOBAL CANCER IMMUNOTHERAPY MARKET, BY APPLICATION, 2014-2022, ($MILLION)
TABLE 6. GLOBAL CANCER IMMUNOTHERAPY MARKET, FOR LUNG CANCER, BY REGION, 2014-2022, ($MILLION)
TABLE 7. GLOBAL CANCER IMMUNOTHERAPY MARKET, FOR BREAST CANCER, BY REGION, 2014-2022, ($MILLION)
TABLE 8. GLOBAL CANCER IMMUNOTHERAPY MARKET, FOR COLORECTAL CANCER, BY REGION, 2014-2022, ($MILLION)
TABLE 9. GLOBAL CANCER IMMUNOTHERAPY MARKET, FOR MELANOMA, BY REGION, 2014-2022, ($MILLION)
TABLE 10. GLOBAL CANCER IMMUNOTHERAPY MARKET, FOR PROSTATE CANCER, BY REGION, 2014-2022, ($MILLION)
TABLE 11. GLOBAL CANCER IMMUNOTHERAPY MARKET, FOR HEAD & NECK CANCER, BY REGION, 2014-2022, ($MILLION)
TABLE 12. GLOBAL CANCER IMMUNOTHERAPY MARKET, FOR OTHER CANCERS, BY REGION, 2014-2022, ($MILLION)
TABLE 13. GLOBAL CANCER IMMUNOTHERAPY MARKET, BY END-USER, 2014-2022, ($MILLION)
TABLE 14. GLOBAL CANCER IMMUNOTHERAPY MARKET, FOR HOSPITALS, BY REGION, 2014-2022, ($MILLION)
TABLE 15. GLOBAL CANCER IMMUNOTHERAPY MARKET, FOR CANCER RESEARCH CENTRES, BY REGION, 2014-2022, ($MILLION)
TABLE 16. GLOBAL CANCER IMMUNOTHERAPY MARKET, FOR CLINICS, BY REGION, 2014-2022, ($MILLION)
TABLE 17. GLOBAL CANCER IMMUNOTHERAPY MARKET, BY REGION, 2014-2022, ($MILLION)
TABLE 18. CANCER IMMUNOTHERAPY MARKET, FOR NORTH AMERICA, BY COUNTRY, 2014-2022, ($MILLION)
TABLE 19. CANCER IMMUNOTHERAPY MARKET, FOR NORTH AMERICA, BY TECHNOLOGY, 2014-2022, ($MILLION)
TABLE 20. CANCER IMMUNOTHERAPY MARKET, FOR NORTH AMERICA, BY APPLICATION, 2014-2022, ($MILLION)
TABLE 21. CANCER IMMUNOTHERAPY MARKET, FOR NORTH AMERICA, BY END-USER, 2014-2022, ($MILLION)
TABLE 22. CANCER IMMUNOTHERAPY MARKET, FOR EUROPE, BY COUNTRY, 2014-2022, ($MILLION)
TABLE 23. CANCER IMMUNOTHERAPY MARKET, FOR EUROPE, BY TECHNOLOGY, 2014-2022, ($MILLION)
TABLE 24. CANCER IMMUNOTHERAPY MARKET, FOR EUROPE, BY APPLICATION, 2014-2022, ($MILLION)
TABLE 25. CANCER IMMUNOTHERAPY MARKET, FOR EUROPE, BY END-USER, 2014-2022, ($MILLION)
TABLE 26. CANCER IMMUNOTHERAPY MARKET, FOR ASIA-PACIFIC, BY COUNTRY, 2014-2022, ($MILLION)
TABLE 27. CANCER IMMUNOTHERAPY MARKET, FOR ASIA-PACIFIC, BY TECHNOLOGY, 2014-2022, ($MILLION)
TABLE 28. CANCER IMMUNOTHERAPY MARKET, FOR ASIA-PACIFIC, BY APPLICATION, 2014-2022, ($MILLION)
TABLE 29. CANCER IMMUNOTHERAPY MARKET, FOR ASIA-PACIFIC, BY END-USER, 2014-2022, ($MILLION)
TABLE 30. CANCER IMMUNOTHERAPY MARKET, FOR LAMEA, BY COUNTRY, 2014-2022, ($MILLION)
TABLE 31. CANCER IMMUNOTHERAPY MARKET, FOR LAMEA, BY TECHNOLOGY, 2014-2022, ($MILLION)
TABLE 32. CANCER IMMUNOTHERAPY MARKET, FOR LAMEA, BY APPLICATION, 2014-2022, ($MILLION)
TABLE 33. CANCER IMMUNOTHERAPY MARKET, FOR LAMEA, BY END-USER, 2014-2022, ($MILLION)
TABLE 34. AMGEN INC. - COMPANY SNAPSHOT
TABLE 35. ADVAXIS INC. - COMPANY SNAPSHOT
TABLE 36. MERCK & CO., INC. - COMPANY SNAPSHOT
TABLE 37. ELI LILLY AND COMPANY - COMPANY SNAPSHOT
TABLE 38. BRISTOL-MYERS SQUIBB COMPANY - COMPANY SNAPSHOT
TABLE 39. PFIZER INC. - COMPANY SNAPSHOT
TABLE 40. NOVARTIS AG - COMPANY SNAPSHOT
TABLE 41. BAYER AG - COMPANY SNAPSHOT
TABLE 42. IMMUNOMEDICS INC. - COMPANY SNAPSHOT
TABLE 43. ASTRAZENECA PLC. - COMPANY SNAPSHOT

List Of Figures

LIST OF FIGURES

FIGURE 1.CANCER IMMUNOTHERAPY: MARKET SEGMENTSTION
FIGURE 2.TOP INVESTMENT POCKETS
FIGURE 3.TOP WINNING STRATEGIES: PERCENTAGE DISTRIBUTION,(2014 2016)
FIGURE 4.TOP WINNING STRATEGIES: NATURE AND TYPE
FIGURE 5.MARKET SHARE ANALYSIS OF CANCER IMMUNOTHERAPY, 2015
FIGURE 6.CANCER IMMUNOTHERAPY: MONOCLONAL ANTIBODIES MARKET, 2014-2022, ($MILLION)
FIGURE 7.CANCER IMMUNOTHERAPY: CYTOKINES & IMMUNOMODULATORS MARKET, 2014-2022, ($MILLION)
FIGURE 8.CANCER IMMUNOTHERAPY: OTHERS THERAPIES MARKET, 2014-2022, ($MILLION)
FIGURE 9.CANCER IMMUNOTHERAPY: LUNG CANCER MARKET, 2014-2022, ($MILLION)
FIGURE 10.CANCER IMMUNOTHERAPY: BREAST CANCER MARKET, 2014-2022, ($MILLION)
FIGURE 11.CANCER IMMUNOTHERAPY: COLORECTAL CANCER MARKET, 2014-2022, ($MILLION)
FIGURE 12.CANCER IMMUNOTHERAPY: MELANOMA MARKET, 2014-2022, ($MILLION)
FIGURE 13.CANCER IMMUNOTHERAPY: PROSTATE CANCER MARKET, 2014-2022, ($MILLION)
FIGURE 14.CANCER IMMUNOTHERAPY: HEAD & NECK CANCERMARKET, 2014-2022, ($MILLION)
FIGURE 15.CANCER IMMUNOTHERAPY: OTHER CANCERS MARKET, 2014-2022, ($MILLION)
FIGURE 16.CANCER IMMUNOTHERAPY: HOSPITALS MARKET, 2014-2022, ($MILLION)
FIGURE 17.CANCER IMMUNOTHERAPY: CANCER RESEARCH CENTRES MARKET, 2014-2022, ($MILLION)
FIGURE 18.CANCER IMMUNOTHERAPY: CLINICS MARKET, 2014-2022, ($MILLION)
FIGURE 19.CANCER IMMUNOTHERAPY: U.S. MARKET, 2014-2022, ($MILLION)
FIGURE 20.CANCER IMMUNOTHERAPY: CANADA MARKET, 2014-2022, ($MILLION)
FIGURE 21.CANCER IMMUNOTHERAPY: MEXICO MARKET, 2014-2022, ($MILLION)
FIGURE 22.CANCER IMMUNOTHERAPY: UK MARKET, 2014-2022, ($MILLION)
FIGURE 23.CANCER IMMUNOTHERAPY: GERMANY MARKET, 2014-2022, ($MILLION)
FIGURE 24.CANCER IMMUNOTHERAPY: FRANCE MARKET, 2014-2022, ($MILLION)
FIGURE 25.CANCER IMMUNOTHERAPY: SPAIN MARKET, 2014-2022, ($MILLION)
FIGURE 26.CANCER IMMUNOTHERAPY: ITALY MARKET, 2014-2022, ($MILLION)
FIGURE 27.CANCER IMMUNOTHERAPY: REST OF EUROPE MARKET, 2014-2022, ($MILLION)
FIGURE 28.CANCER IMMUNOTHERAPY: CHINA MARKET, 2014-2022, ($MILLION)
FIGURE 29.CANCER IMMUNOTHERAPY: JAPAN MARKET, 2014-2022, ($MILLION)
FIGURE 30.CANCER IMMUNOTHERAPY: INDIA MARKET, 2014-2022, ($MILLION)
FIGURE 31.CANCER IMMUNOTHERAPY: REST OF ASIA-PACIFIC MARKET, 2014-2022, ($MILLION)
FIGURE 32.CANCER IMMUNOTHERAPY: LATIN AMERICA MARKET, 2014-2022, ($MILLION)
FIGURE 33.CANCER IMMUNOTHERAPY: MIDDLE EAST MARKET, 2014-2022, ($MILLION)
FIGURE 34.CANCER IMMUNOTHERAPY: AFRICA MARKET, 2014-2022, ($MILLION)